V.THRM | 2 hours ago
Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that on February 4, 2022 the U.S. Patent and Trademark Office allowed a U.S. patent application (US 15/787,599) which covers a device that can apply heat and antimicrobial treatment through a detachable applicator surface comprising copper or silver to provide heat conductivity and a source of antimicrobial agent. The device also includes a light source. This U.S. patent applies to both Therma Bright’sInterceptCS™ Cold Sore Prevention Device and TherOZap™ Insect Bite Relief Device.
Specific to the InterceptCS™ device, this heat and antimicrobial treatment technology is combined as the solution for the prevention of cold sores. As for the TherOZap™ device, the treatment technology aims to reduce the inflammatory response, relieving the symptoms of pain, itch and inflammation associated with insect bites and stings. Furthermore, as shared in earlier press releases, the Company engaged a top Virology Research Laboratory in Canada to study the TherOZap™ technology’s ability to inactivate live Zika virus in culture media and that the TherOZap™,which utilizes specialized materials, coatings and heat, was able to limit Zika virus (“ZIKV”) replication in cell cultures.
“This is exciting news for Therma Bright and our TherOZap™ Insect Relief Device and InterceptCS™ Cold Sore Prevention Device,” shared Rob Fia, CEO of Therma Bright. “This allowed U.S. Patent Application further protects our valued intellectual property (IP) as we continue to transform innovation into wellness.”
Therma Bright is currently undergoing design upgrades to both devices and expects to complete prototyping during Q2. In addition, the Company plans to continue its research with the new TherOZap™ design on Zika and other mosquito-borne diseases during 2022.
